PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction
Abstract Aims PCSK9 is secreted into the circulation, mainly by the liver, and interacts with low-density lipoprotein receptor (LDLR) homologous and non-homologous receptors, including CD36, thus favouring their intracellular degradation. As PCSK9 deficiency increases the expression of lipids and li...
Gespeichert in:
Veröffentlicht in: | European heart journal 2021-08, Vol.42 (32), p.3078-3090 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3090 |
---|---|
container_issue | 32 |
container_start_page | 3078 |
container_title | European heart journal |
container_volume | 42 |
creator | Da Dalt, Lorenzo Castiglioni, Laura Baragetti, Andrea Audano, Matteo Svecla, Monika Bonacina, Fabrizia Pedretti, Silvia Uboldi, Patrizia Benzoni, Patrizia Giannetti, Federica Barbuti, Andrea Pellegatta, Fabio Indino, Serena Donetti, Elena Sironi, Luigi Mitro, Nico Catapano, Alberico Luigi Norata, Giuseppe Danilo |
description | Abstract
Aims
PCSK9 is secreted into the circulation, mainly by the liver, and interacts with low-density lipoprotein receptor (LDLR) homologous and non-homologous receptors, including CD36, thus favouring their intracellular degradation. As PCSK9 deficiency increases the expression of lipids and lipoprotein receptors, thus contributing to cellular lipid accumulation, we investigated whether this could affect heart metabolism and function.
Methods and results
Wild-type (WT), Pcsk9 KO, Liver conditional Pcsk9 KO and Pcsk9/Ldlr double KO male mice were fed for 20 weeks with a standard fat diet and then exercise resistance, muscle strength, and heart characteristics were evaluated. Pcsk9 KO presented reduced running resistance coupled to echocardiographic abnormalities suggestive of heart failure with preserved ejection fraction (HFpEF). Heart mitochondrial activity, following maximal coupled and uncoupled respiration, was reduced in Pcsk9 KO mice compared to WT mice and was coupled to major changes in cardiac metabolism together with increased expression of LDLR and CD36 and with lipid accumulation. A similar phenotype was observed in Pcsk9/Ldlr DKO, thus excluding a contribution for LDLR to cardiac impairment observed in Pcsk9 KO mice. Heart function profiling of the liver selective Pcsk9 KO model further excluded the involvement of circulating PCSK9 in the development of HFpEF, pointing to a possible role locally produced PCSK9. Concordantly, carriers of the R46L loss-of-function variant for PCSK9 presented increased left ventricular mass but similar ejection fraction compared to matched control subjects.
Conclusion
PCSK9 deficiency impacts cardiac lipid metabolism in an LDLR independent manner and contributes to the development of HFpEF.
Graphical Abstract
Impact of Pcsk9 deficiency on cardiac function and mitochondrial metabolism. Pcsk9 deficiency is associated with increased heart left ventricular thickness and reduced running performance independently of skeletal muscle alterations. Electron microscopy analysis showed increased cardiac accumulation of lipid droplets associated with a reduced density of mitochondrial cristae; this proffunctionally translated into impaired oxidative phosphorylation and mitochondrial metabolism in PCSK9 KO hearts. |
doi_str_mv | 10.1093/eurheartj/ehab431 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8380058</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehab431</oup_id><sourcerecordid>2551208400</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-eef0329481826500cf442b91b06ae05d63e3cef979e564cf903d7ad1d24a37193</originalsourceid><addsrcrecordid>eNqNkUuLVDEQhYMoTjv6A9xIli68TuXZyUaQxhcOKKjgLuQmFTvNfbTJvT3Mv_c63Ta6c1UF55yvCg4hTxm8ZGDFFc5li75Muyvc-lYKdo-smOK8sVqq-2QFzKpGa_P9gjyqdQcARjP9kFwIyRVnhq1I-Lz58tHSiCmHjEO4pQVvcsFK78i0x8m3Y5drT_0QaSz5cNaSz91ckN7kaUv3SwbLASPFHYYpjwNNxd8tj8mD5LuKT07zknx7--br5n1z_endh83r6yZIoacGMYHgVhpmuFYAIUnJW8ta0B5BRS1QBEx2bVFpGZIFEdc-ssilF2tmxSV5deTu57bHGHCYiu_cvuTel1s3-uz-VYa8dT_GgzPCACizAJ6fAGX8OWOdXJ9rwK7zA45zdVwpxsFIgMXKjtZQxloLpvMZBu53Oe5cjjuVs2Se_f3fOfGnjcXw4mgY5_1_8H4Bv0-gjA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2551208400</pqid></control><display><type>article</type><title>PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction</title><source>MEDLINE</source><source>Oxford University Press Journals Current</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Da Dalt, Lorenzo ; Castiglioni, Laura ; Baragetti, Andrea ; Audano, Matteo ; Svecla, Monika ; Bonacina, Fabrizia ; Pedretti, Silvia ; Uboldi, Patrizia ; Benzoni, Patrizia ; Giannetti, Federica ; Barbuti, Andrea ; Pellegatta, Fabio ; Indino, Serena ; Donetti, Elena ; Sironi, Luigi ; Mitro, Nico ; Catapano, Alberico Luigi ; Norata, Giuseppe Danilo</creator><creatorcontrib>Da Dalt, Lorenzo ; Castiglioni, Laura ; Baragetti, Andrea ; Audano, Matteo ; Svecla, Monika ; Bonacina, Fabrizia ; Pedretti, Silvia ; Uboldi, Patrizia ; Benzoni, Patrizia ; Giannetti, Federica ; Barbuti, Andrea ; Pellegatta, Fabio ; Indino, Serena ; Donetti, Elena ; Sironi, Luigi ; Mitro, Nico ; Catapano, Alberico Luigi ; Norata, Giuseppe Danilo</creatorcontrib><description>Abstract
Aims
PCSK9 is secreted into the circulation, mainly by the liver, and interacts with low-density lipoprotein receptor (LDLR) homologous and non-homologous receptors, including CD36, thus favouring their intracellular degradation. As PCSK9 deficiency increases the expression of lipids and lipoprotein receptors, thus contributing to cellular lipid accumulation, we investigated whether this could affect heart metabolism and function.
Methods and results
Wild-type (WT), Pcsk9 KO, Liver conditional Pcsk9 KO and Pcsk9/Ldlr double KO male mice were fed for 20 weeks with a standard fat diet and then exercise resistance, muscle strength, and heart characteristics were evaluated. Pcsk9 KO presented reduced running resistance coupled to echocardiographic abnormalities suggestive of heart failure with preserved ejection fraction (HFpEF). Heart mitochondrial activity, following maximal coupled and uncoupled respiration, was reduced in Pcsk9 KO mice compared to WT mice and was coupled to major changes in cardiac metabolism together with increased expression of LDLR and CD36 and with lipid accumulation. A similar phenotype was observed in Pcsk9/Ldlr DKO, thus excluding a contribution for LDLR to cardiac impairment observed in Pcsk9 KO mice. Heart function profiling of the liver selective Pcsk9 KO model further excluded the involvement of circulating PCSK9 in the development of HFpEF, pointing to a possible role locally produced PCSK9. Concordantly, carriers of the R46L loss-of-function variant for PCSK9 presented increased left ventricular mass but similar ejection fraction compared to matched control subjects.
Conclusion
PCSK9 deficiency impacts cardiac lipid metabolism in an LDLR independent manner and contributes to the development of HFpEF.
Graphical Abstract
Impact of Pcsk9 deficiency on cardiac function and mitochondrial metabolism. Pcsk9 deficiency is associated with increased heart left ventricular thickness and reduced running performance independently of skeletal muscle alterations. Electron microscopy analysis showed increased cardiac accumulation of lipid droplets associated with a reduced density of mitochondrial cristae; this proffunctionally translated into impaired oxidative phosphorylation and mitochondrial metabolism in PCSK9 KO hearts.</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehab431</identifier><identifier>PMID: 34252181</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Animals ; Heart Failure - genetics ; Male ; Mice ; Mice, Knockout ; Proprotein Convertase 9 - genetics ; Receptors, LDL - genetics ; Stroke Volume ; Translational Research</subject><ispartof>European heart journal, 2021-08, Vol.42 (32), p.3078-3090</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-eef0329481826500cf442b91b06ae05d63e3cef979e564cf903d7ad1d24a37193</citedby><cites>FETCH-LOGICAL-c436t-eef0329481826500cf442b91b06ae05d63e3cef979e564cf903d7ad1d24a37193</cites><orcidid>0000-0002-5634-5863 ; 0000-0002-7593-2094 ; 0000-0002-6298-8689 ; 0000-0002-1785-5529 ; 0000-0002-5000-3619 ; 0000-0003-2791-4526 ; 0000-0002-7269-7308 ; 0000-0002-6216-1999 ; 0000-0001-6404-6321 ; 0000-0002-4738-3454 ; 0000-0002-3227-0553 ; 0000-0002-2611-1177 ; 0000-0002-4521-4913 ; 0000-0002-6081-1257 ; 0000-0002-9879-1853 ; 0000-0002-3371-3301</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34252181$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Da Dalt, Lorenzo</creatorcontrib><creatorcontrib>Castiglioni, Laura</creatorcontrib><creatorcontrib>Baragetti, Andrea</creatorcontrib><creatorcontrib>Audano, Matteo</creatorcontrib><creatorcontrib>Svecla, Monika</creatorcontrib><creatorcontrib>Bonacina, Fabrizia</creatorcontrib><creatorcontrib>Pedretti, Silvia</creatorcontrib><creatorcontrib>Uboldi, Patrizia</creatorcontrib><creatorcontrib>Benzoni, Patrizia</creatorcontrib><creatorcontrib>Giannetti, Federica</creatorcontrib><creatorcontrib>Barbuti, Andrea</creatorcontrib><creatorcontrib>Pellegatta, Fabio</creatorcontrib><creatorcontrib>Indino, Serena</creatorcontrib><creatorcontrib>Donetti, Elena</creatorcontrib><creatorcontrib>Sironi, Luigi</creatorcontrib><creatorcontrib>Mitro, Nico</creatorcontrib><creatorcontrib>Catapano, Alberico Luigi</creatorcontrib><creatorcontrib>Norata, Giuseppe Danilo</creatorcontrib><title>PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction</title><title>European heart journal</title><addtitle>Eur Heart J</addtitle><description>Abstract
Aims
PCSK9 is secreted into the circulation, mainly by the liver, and interacts with low-density lipoprotein receptor (LDLR) homologous and non-homologous receptors, including CD36, thus favouring their intracellular degradation. As PCSK9 deficiency increases the expression of lipids and lipoprotein receptors, thus contributing to cellular lipid accumulation, we investigated whether this could affect heart metabolism and function.
Methods and results
Wild-type (WT), Pcsk9 KO, Liver conditional Pcsk9 KO and Pcsk9/Ldlr double KO male mice were fed for 20 weeks with a standard fat diet and then exercise resistance, muscle strength, and heart characteristics were evaluated. Pcsk9 KO presented reduced running resistance coupled to echocardiographic abnormalities suggestive of heart failure with preserved ejection fraction (HFpEF). Heart mitochondrial activity, following maximal coupled and uncoupled respiration, was reduced in Pcsk9 KO mice compared to WT mice and was coupled to major changes in cardiac metabolism together with increased expression of LDLR and CD36 and with lipid accumulation. A similar phenotype was observed in Pcsk9/Ldlr DKO, thus excluding a contribution for LDLR to cardiac impairment observed in Pcsk9 KO mice. Heart function profiling of the liver selective Pcsk9 KO model further excluded the involvement of circulating PCSK9 in the development of HFpEF, pointing to a possible role locally produced PCSK9. Concordantly, carriers of the R46L loss-of-function variant for PCSK9 presented increased left ventricular mass but similar ejection fraction compared to matched control subjects.
Conclusion
PCSK9 deficiency impacts cardiac lipid metabolism in an LDLR independent manner and contributes to the development of HFpEF.
Graphical Abstract
Impact of Pcsk9 deficiency on cardiac function and mitochondrial metabolism. Pcsk9 deficiency is associated with increased heart left ventricular thickness and reduced running performance independently of skeletal muscle alterations. Electron microscopy analysis showed increased cardiac accumulation of lipid droplets associated with a reduced density of mitochondrial cristae; this proffunctionally translated into impaired oxidative phosphorylation and mitochondrial metabolism in PCSK9 KO hearts.</description><subject>Animals</subject><subject>Heart Failure - genetics</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Proprotein Convertase 9 - genetics</subject><subject>Receptors, LDL - genetics</subject><subject>Stroke Volume</subject><subject>Translational Research</subject><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNqNkUuLVDEQhYMoTjv6A9xIli68TuXZyUaQxhcOKKjgLuQmFTvNfbTJvT3Mv_c63Ta6c1UF55yvCg4hTxm8ZGDFFc5li75Muyvc-lYKdo-smOK8sVqq-2QFzKpGa_P9gjyqdQcARjP9kFwIyRVnhq1I-Lz58tHSiCmHjEO4pQVvcsFK78i0x8m3Y5drT_0QaSz5cNaSz91ckN7kaUv3SwbLASPFHYYpjwNNxd8tj8mD5LuKT07zknx7--br5n1z_endh83r6yZIoacGMYHgVhpmuFYAIUnJW8ta0B5BRS1QBEx2bVFpGZIFEdc-ssilF2tmxSV5deTu57bHGHCYiu_cvuTel1s3-uz-VYa8dT_GgzPCACizAJ6fAGX8OWOdXJ9rwK7zA45zdVwpxsFIgMXKjtZQxloLpvMZBu53Oe5cjjuVs2Se_f3fOfGnjcXw4mgY5_1_8H4Bv0-gjA</recordid><startdate>20210821</startdate><enddate>20210821</enddate><creator>Da Dalt, Lorenzo</creator><creator>Castiglioni, Laura</creator><creator>Baragetti, Andrea</creator><creator>Audano, Matteo</creator><creator>Svecla, Monika</creator><creator>Bonacina, Fabrizia</creator><creator>Pedretti, Silvia</creator><creator>Uboldi, Patrizia</creator><creator>Benzoni, Patrizia</creator><creator>Giannetti, Federica</creator><creator>Barbuti, Andrea</creator><creator>Pellegatta, Fabio</creator><creator>Indino, Serena</creator><creator>Donetti, Elena</creator><creator>Sironi, Luigi</creator><creator>Mitro, Nico</creator><creator>Catapano, Alberico Luigi</creator><creator>Norata, Giuseppe Danilo</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5634-5863</orcidid><orcidid>https://orcid.org/0000-0002-7593-2094</orcidid><orcidid>https://orcid.org/0000-0002-6298-8689</orcidid><orcidid>https://orcid.org/0000-0002-1785-5529</orcidid><orcidid>https://orcid.org/0000-0002-5000-3619</orcidid><orcidid>https://orcid.org/0000-0003-2791-4526</orcidid><orcidid>https://orcid.org/0000-0002-7269-7308</orcidid><orcidid>https://orcid.org/0000-0002-6216-1999</orcidid><orcidid>https://orcid.org/0000-0001-6404-6321</orcidid><orcidid>https://orcid.org/0000-0002-4738-3454</orcidid><orcidid>https://orcid.org/0000-0002-3227-0553</orcidid><orcidid>https://orcid.org/0000-0002-2611-1177</orcidid><orcidid>https://orcid.org/0000-0002-4521-4913</orcidid><orcidid>https://orcid.org/0000-0002-6081-1257</orcidid><orcidid>https://orcid.org/0000-0002-9879-1853</orcidid><orcidid>https://orcid.org/0000-0002-3371-3301</orcidid></search><sort><creationdate>20210821</creationdate><title>PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction</title><author>Da Dalt, Lorenzo ; Castiglioni, Laura ; Baragetti, Andrea ; Audano, Matteo ; Svecla, Monika ; Bonacina, Fabrizia ; Pedretti, Silvia ; Uboldi, Patrizia ; Benzoni, Patrizia ; Giannetti, Federica ; Barbuti, Andrea ; Pellegatta, Fabio ; Indino, Serena ; Donetti, Elena ; Sironi, Luigi ; Mitro, Nico ; Catapano, Alberico Luigi ; Norata, Giuseppe Danilo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-eef0329481826500cf442b91b06ae05d63e3cef979e564cf903d7ad1d24a37193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Heart Failure - genetics</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Proprotein Convertase 9 - genetics</topic><topic>Receptors, LDL - genetics</topic><topic>Stroke Volume</topic><topic>Translational Research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Da Dalt, Lorenzo</creatorcontrib><creatorcontrib>Castiglioni, Laura</creatorcontrib><creatorcontrib>Baragetti, Andrea</creatorcontrib><creatorcontrib>Audano, Matteo</creatorcontrib><creatorcontrib>Svecla, Monika</creatorcontrib><creatorcontrib>Bonacina, Fabrizia</creatorcontrib><creatorcontrib>Pedretti, Silvia</creatorcontrib><creatorcontrib>Uboldi, Patrizia</creatorcontrib><creatorcontrib>Benzoni, Patrizia</creatorcontrib><creatorcontrib>Giannetti, Federica</creatorcontrib><creatorcontrib>Barbuti, Andrea</creatorcontrib><creatorcontrib>Pellegatta, Fabio</creatorcontrib><creatorcontrib>Indino, Serena</creatorcontrib><creatorcontrib>Donetti, Elena</creatorcontrib><creatorcontrib>Sironi, Luigi</creatorcontrib><creatorcontrib>Mitro, Nico</creatorcontrib><creatorcontrib>Catapano, Alberico Luigi</creatorcontrib><creatorcontrib>Norata, Giuseppe Danilo</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Da Dalt, Lorenzo</au><au>Castiglioni, Laura</au><au>Baragetti, Andrea</au><au>Audano, Matteo</au><au>Svecla, Monika</au><au>Bonacina, Fabrizia</au><au>Pedretti, Silvia</au><au>Uboldi, Patrizia</au><au>Benzoni, Patrizia</au><au>Giannetti, Federica</au><au>Barbuti, Andrea</au><au>Pellegatta, Fabio</au><au>Indino, Serena</au><au>Donetti, Elena</au><au>Sironi, Luigi</au><au>Mitro, Nico</au><au>Catapano, Alberico Luigi</au><au>Norata, Giuseppe Danilo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction</atitle><jtitle>European heart journal</jtitle><addtitle>Eur Heart J</addtitle><date>2021-08-21</date><risdate>2021</risdate><volume>42</volume><issue>32</issue><spage>3078</spage><epage>3090</epage><pages>3078-3090</pages><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract
Aims
PCSK9 is secreted into the circulation, mainly by the liver, and interacts with low-density lipoprotein receptor (LDLR) homologous and non-homologous receptors, including CD36, thus favouring their intracellular degradation. As PCSK9 deficiency increases the expression of lipids and lipoprotein receptors, thus contributing to cellular lipid accumulation, we investigated whether this could affect heart metabolism and function.
Methods and results
Wild-type (WT), Pcsk9 KO, Liver conditional Pcsk9 KO and Pcsk9/Ldlr double KO male mice were fed for 20 weeks with a standard fat diet and then exercise resistance, muscle strength, and heart characteristics were evaluated. Pcsk9 KO presented reduced running resistance coupled to echocardiographic abnormalities suggestive of heart failure with preserved ejection fraction (HFpEF). Heart mitochondrial activity, following maximal coupled and uncoupled respiration, was reduced in Pcsk9 KO mice compared to WT mice and was coupled to major changes in cardiac metabolism together with increased expression of LDLR and CD36 and with lipid accumulation. A similar phenotype was observed in Pcsk9/Ldlr DKO, thus excluding a contribution for LDLR to cardiac impairment observed in Pcsk9 KO mice. Heart function profiling of the liver selective Pcsk9 KO model further excluded the involvement of circulating PCSK9 in the development of HFpEF, pointing to a possible role locally produced PCSK9. Concordantly, carriers of the R46L loss-of-function variant for PCSK9 presented increased left ventricular mass but similar ejection fraction compared to matched control subjects.
Conclusion
PCSK9 deficiency impacts cardiac lipid metabolism in an LDLR independent manner and contributes to the development of HFpEF.
Graphical Abstract
Impact of Pcsk9 deficiency on cardiac function and mitochondrial metabolism. Pcsk9 deficiency is associated with increased heart left ventricular thickness and reduced running performance independently of skeletal muscle alterations. Electron microscopy analysis showed increased cardiac accumulation of lipid droplets associated with a reduced density of mitochondrial cristae; this proffunctionally translated into impaired oxidative phosphorylation and mitochondrial metabolism in PCSK9 KO hearts.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>34252181</pmid><doi>10.1093/eurheartj/ehab431</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-5634-5863</orcidid><orcidid>https://orcid.org/0000-0002-7593-2094</orcidid><orcidid>https://orcid.org/0000-0002-6298-8689</orcidid><orcidid>https://orcid.org/0000-0002-1785-5529</orcidid><orcidid>https://orcid.org/0000-0002-5000-3619</orcidid><orcidid>https://orcid.org/0000-0003-2791-4526</orcidid><orcidid>https://orcid.org/0000-0002-7269-7308</orcidid><orcidid>https://orcid.org/0000-0002-6216-1999</orcidid><orcidid>https://orcid.org/0000-0001-6404-6321</orcidid><orcidid>https://orcid.org/0000-0002-4738-3454</orcidid><orcidid>https://orcid.org/0000-0002-3227-0553</orcidid><orcidid>https://orcid.org/0000-0002-2611-1177</orcidid><orcidid>https://orcid.org/0000-0002-4521-4913</orcidid><orcidid>https://orcid.org/0000-0002-6081-1257</orcidid><orcidid>https://orcid.org/0000-0002-9879-1853</orcidid><orcidid>https://orcid.org/0000-0002-3371-3301</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0195-668X |
ispartof | European heart journal, 2021-08, Vol.42 (32), p.3078-3090 |
issn | 0195-668X 1522-9645 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8380058 |
source | MEDLINE; Oxford University Press Journals Current; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Animals Heart Failure - genetics Male Mice Mice, Knockout Proprotein Convertase 9 - genetics Receptors, LDL - genetics Stroke Volume Translational Research |
title | PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T00%3A43%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PCSK9%20deficiency%20rewires%20heart%20metabolism%20and%20drives%20heart%20failure%20with%20preserved%20ejection%20fraction&rft.jtitle=European%20heart%20journal&rft.au=Da%20Dalt,%20Lorenzo&rft.date=2021-08-21&rft.volume=42&rft.issue=32&rft.spage=3078&rft.epage=3090&rft.pages=3078-3090&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehab431&rft_dat=%3Cproquest_pubme%3E2551208400%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2551208400&rft_id=info:pmid/34252181&rft_oup_id=10.1093/eurheartj/ehab431&rfr_iscdi=true |